Relative Cost Differences of Initial Treatment Strategies for Newly Diagnosed Opioid Use Disorder: A Cohort Study.

"In the past 36 months, S.E.W. has received research support through Massachusetts General Hospital from the National Institutes of Health National Institute of Drug Abuse (1R01DA044526-01A1 and 3UG1DA015831-17S2), the Substance Abuse and Mental Health Services Administration (1H79TI081442-01), the Health Resources and Services Administration (1T25HP37602-01), the Laura and John Arnold Foundation, and received salary support from OptumLabs, Celero Systems, Alosa Health, and UptoDate, and textbook royalties from Springer. In the past 36 months, O.A. has received research support from Boston University School of Public Health, Department of Veterans Affairs, Optum via UnitedHealthcare and the American Physical Therapy Association, and has been an employee of OptumLabs. In the past 36 months, C.E.C. has received research support through Boston School of Public Health from the National Institutes of Health (NIH) (P30 AG13846; 1U01AA021989; R01 AR055557), and from NIH via the National Institute of Neurological Disorders and Stroke (1U01NS093334-01; 1U01NS086659), and from NIH via the National Institute on Alcohol Abuse and Alcoholism (U24 AA020779; 1R01AA021335), and from the National Institute of Allergy and Infectious Diseases (U01 AA020776), and from NIH via the National Institute on Deafness and Other Communication Disorders (P50 DC013027), and from NIH via the National Center for Advancing Translational Sciences (1UL1TR001430), and from NIH via the National Institute on Minority Health and Health Disparities (U24 MD006964), and from NIH via the National Institute on Drug Abuse (R01DA032082; R01 DA037768), and from the Department of Defense (W81XWH-13-2-0072), and has been an employee of OptumLabs. In the past 36 months, J.T.M., W.H.C., and D.M.S. have been employees of OptumLabs. In the past 36 months, F.A. has been an employee of Optum—UnitedHealth Group. In the past 36 months, M.R.L. has received research support through Boston Medical Center from the National Institutes of Health via the National Institute on Drug Abuse (K23DA042168 and UM1DA049412) and the National Center for Advancing Translational Sciences (1UL1TR001430), Centers for Disease Control and Prevention (U01CE002780), Food and Drug Administration (HHSF2232009100006I), Office of National Drug Control Policy/University of Baltimore (G1799ONDCP06B), a Boston University School of Medicine Department of Medicine Career Investment Award, and served as a consultant for opioid-related health services research to the Harvard Medical School Department of Population Medicine."

"Funding for this work was provided by Optum—UnitedHealth Group. In the past 36 months, S.E.W. has received research support through Massachusetts General Hospital from the National Institutes of Health National Institute of Drug Abuse (1R01DA044526-01A1 and 3UG1DA015831-17S2), the Substance Abuse and Mental Health Services Administration (1H79TI081442-01), the Health Resources and Services Administration (1T25HP37602-01), the Laura and John Arnold Foundation, and received salary support from OptumLabs, Celero Systems, Alosa Health, and UptoDate, and textbook royalties from Springer. In the past 36 months, O.A. has received research support from Boston University School of Public Health, Department of Veterans Affairs, Optum via UnitedHealthcare and the American Physical Therapy Association, and has been an employee of OptumLabs. In the past 36 months, C.E.C. has received research support through Boston School of Public Health from the National Institutes of Health (NIH) (P30 AG13846; 1U01AA021989; R01 AR055557), and from NIH via the National Institute of Neurological Disorders and Stroke (1U01NS093334-01; 1U01NS086659), and from NIH via the National Institute on Alcohol Abuse and Alcoholism (U24 AA020779; 1R01AA021335), and from the National Institute of Allergy and Infectious Diseases (U01 AA020776), and from NIH via the National Institute on Deafness and Other Communication Disorders (P50 DC013027), and from NIH via the National Center for Advancing Translational Sciences (1UL1TR001430), and from NIH via the National Institute on Minority Health and Health Disparities (U24 MD006964), and from NIH via the National Institute on Drug Abuse (R01DA032082; R01 DA037768), and from the Department of Defense (W81XWH-13-2-0072), and has been an employee of OptumLabs. In the past 36 months, J.T.M., W.H.C., and D.M.S. have been employees of OptumLabs. In the past 36 months, F.A. has been an employee of Optum—UnitedHealth Group. In the past 36 months, M.R.L. has received research support through Boston Medical Center from the National Institutes of Health via the National Institute on Drug Abuse (K23DA042168 and UM1DA049412) and the National Center for Advancing Translational Sciences (1UL1TR001430), Centers for Disease Control and Prevention (U01CE002780), Food and Drug Administration (HHSF2232009100006I), Office of National Drug Control Policy/University of Baltimore (G1799ONDCP06B), a Boston University School of Medicine Department of Medicine Career Investment Award, and served as a consultant for opioid-related health services research to the Harvard Medical School Department of Population Medicine."